Norman S Lowenbraun, MD
Cardiovascular Disease (Cardiology) · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 32
- 8 carriers
- Offices
- 2
Offices
2 locations · County of Santa Clara · 1,000 clinicians in this group
Hospitals listed: Santa Clara Valley Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
32 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lowenbraun’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
32 of 32 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G70729 · Current
Licensed to practise in California · since 1991 · expires 2028-10-31 · New York Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$598,960
Medicare paid this office $598,960 for 597 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 123 | $187,530 | $1,525 |
| Return visit (30+ min) | 472 | $102,894 | $108 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 109 | $97,069 | $882 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 123 | $96,953 | $394 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 218 | $42,566 | $189 |
See all 18 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 123 | $187,530 | $1,525 |
| Return visit (30+ min) | 472 | $102,894 | $108 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 109 | $97,069 | $882 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 123 | $96,953 | $394 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 218 | $42,566 | $189 |
| New patient visit (60+ min) | 108 | $20,632 | $191 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 156 | $11,067 | $70 |
| Short return visit (20+ min) | 85 | $8,390 | $76 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 117 | $7,443 | $63 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 12 | $5,036 | $420 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 11 | $2,695 | $122 |
| Programming of dual lead pacemaker system | 22 | $2,526 | $68 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 185 | $2,369 | $12 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 109 | $2,316 | $21 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 118 | $1,962 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 33 | $1,670 | $51 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 14 | $1,044 | $47 |
| Infusion, normal saline solution, 250 cc | 135 | $502 | None |
Who their Medicare patients are
597 Original Medicare patients in 2024. Average age 78 · Women 47% · Also on Medicaid 10% · Health risk score 1.30. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 53% · Diabetes 34% · Atrial fibrillation 31% · Chronic kidney disease 27% · Heart failure 24% · Cancer 20% · COPD 13% · Depression 13% · Stroke 11% · Dementia 8%.
The office billed $1,271,610, Medicare allowed $780,047 and paid $598,960; for 8,872 services of 30 kinds; $2,635 of it was for drugs given in the office and $596,324 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 597 | 8,872 | 78 | 1.30 | $1,271,610 | $598,960 |
| 2023 | 682 | 8,534 | 78 | 1.47 | $1,292,606 | $631,107 |
| 2022 | 645 | 8,632 | 78 | 1.35 | $1,220,118 | $595,636 |
| 2021 | 633 | 8,334 | 78 | 1.35 | $1,270,794 | $609,521 |
| 2020 | 827 | 7,398 | 77 | 1.73 | $997,522 | $439,903 |
| 2019 | 750 | 9,186 | 78 | 1.52 | $968,668 | $434,214 |
| 2018 | 733 | 8,677 | 78 | 1.47 | $978,540 | $449,129 |
| 2017 | 858 | 10,525 | 78 | 1.64 | $1,110,026 | $462,984 |
| 2016 | 814 | 13,687 | 78 | 1.50 | $1,246,359 | $507,152 |
| 2015 | 477 | 11,185 | 77 | 1.44 | $803,084 | $381,332 |
| 2014 | 499 | 11,976 | 77 | 1.45 | $718,050 | $455,137 |
| 2013 | 491 | 2,990 | 77 | 1.51 | $435,765 | $315,119 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 20 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 120 | $192,590 | $1,605 |
| Return visit (30+ min) | 497 | $112,996 | $110 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 107 | $102,309 | $956 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 121 | $101,012 | $417 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 216 | $44,647 | $200 |
| New patient visit (60+ min) | 86 | $16,427 | $191 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 149 | $10,667 | $72 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 114 | $8,012 | $70 |
| Short return visit (20+ min) | 77 | $6,577 | $71 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 110 | $6,113 | $55 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 11 | $4,966 | $451 |
| Programming of dual lead pacemaker system | 33 | $3,647 | $74 |
| Injection, regadenoson, 0.1 mg | 19 | $3,435 | None |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 108 | $2,459 | $23 |
| Long return visit (40+ min) | 14 | $2,307 | $165 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 176 | $2,262 | $13 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 105 | $1,971 | None |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 11 | $1,955 | $89 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 18 | $848 | $47 |
| Infusion, normal saline solution, 250 cc | 131 | $451 | None |
2022: 19 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 110 | $176,867 | $1,608 |
| Return visit (30+ min) | 526 | $121,490 | $109 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 93 | $95,099 | $1,001 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 110 | $91,866 | $418 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 193 | $39,805 | $197 |
| Short return visit (20+ min) | 124 | $13,608 | $80 |
| New patient visit (60+ min) | 67 | $12,787 | $191 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 124 | $9,131 | $72 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 95 | $6,692 | $68 |
| Programming of dual lead pacemaker system | 35 | $3,619 | $71 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 12 | $2,904 | $242 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 42 | $2,361 | $56 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 169 | $2,244 | $13 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 93 | $2,067 | $22 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 105 | $1,860 | None |
| New patient visit (45+ min) | 14 | $1,444 | $103 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 14 | $808 | $51 |
| Infusion, normal saline solution, 250 cc | 116 | $460 | None |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 12 | $274 | $23 |
2021: 20 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 103 | $173,297 | $1,666 |
| Return visit (30+ min) | 501 | $113,324 | $109 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 134 | $108,839 | $800 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 103 | $87,969 | $423 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 198 | $43,831 | $206 |
| Short return visit (20+ min) | 117 | $13,872 | $81 |
| New patient visit (60+ min) | 54 | $10,903 | $202 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 19 | $9,908 | $521 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 133 | $9,734 | $72 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 133 | $9,613 | $72 |
| Programming of dual lead pacemaker system | 32 | $4,151 | $74 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 20 | $3,861 | $99 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 134 | $3,127 | $23 |
| New patient visit (45+ min) | 24 | $2,284 | $95 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 99 | $2,140 | None |
| Injection, regadenoson, 0.1 mg | 11 | $2,091 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 27 | $1,617 | $60 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 105 | $1,582 | $14 |
| Infusion, normal saline solution, 250 cc | 123 | $484 | None |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 20 | $483 | $23 |
2020: 21 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 88 | $147,722 | $1,679 |
| Return visit (30+ min) | 471 | $84,280 | $88 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 88 | $73,749 | $421 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 174 | $36,301 | $199 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 35 | $27,814 | $795 |
| Short return visit (20+ min) | 165 | $13,566 | $62 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 104 | $7,372 | $71 |
| New patient visit (60+ min) | 40 | $7,345 | $184 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 13 | $6,750 | $519 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 72 | $5,880 | $78 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 67 | $4,160 | $62 |
| Programming of dual lead pacemaker system | 37 | $3,954 | $67 |
| New patient visit (45+ min) | 29 | $2,802 | $97 |
| Long return visit (40+ min) | 24 | $2,639 | $110 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 13 | $2,558 | $98 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 92 | $1,990 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 83 | $1,465 | $16 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 158 | $1,185 | $7 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 35 | $870 | $25 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 27 | $568 | $20 |
| Infusion, normal saline solution, 250 cc | 102 | $395 | None |
2019: 19 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 84 | $132,932 | $1,564 |
| Return visit (30+ min) | 530 | $96,761 | $90 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 84 | $70,710 | $416 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 198 | $42,324 | $204 |
| Short return visit (20+ min) | 141 | $11,989 | $66 |
| New patient visit (60+ min) | 68 | $11,961 | $176 |
| Long return visit (40+ min) | 80 | $11,485 | $110 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 19 | $9,768 | $514 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 109 | $7,676 | $69 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 79 | $6,375 | $79 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 80 | $5,302 | $66 |
| Programming of dual lead pacemaker system | 48 | $4,644 | $60 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 19 | $3,694 | $97 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 86 | $3,284 | None |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 15 | $3,116 | $208 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,764 | $184 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 140 | $2,390 | $16 |
| New patient visit (45+ min) | 24 | $2,263 | $94 |
| Infusion, normal saline solution, 250 cc | 103 | $364 | None |
2018: 20 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 89 | $145,422 | $1,634 |
| Return visit (30+ min) | 556 | $113,835 | $95 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 88 | $47,936 | $272 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 202 | $44,855 | $213 |
| Long return visit (40+ min) | 76 | $12,371 | $130 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 21 | $11,293 | $538 |
| New patient visit (60+ min) | 56 | $10,377 | $185 |
| Short return visit (20+ min) | 97 | $8,789 | $66 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 117 | $8,657 | $73 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 82 | $7,196 | $86 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 65 | $4,542 | $69 |
| Programming of dual lead pacemaker system | 45 | $4,375 | $56 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 21 | $4,109 | $98 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 197 | $3,619 | $16 |
| Injection, regadenoson, 0.1 mg | 20 | $3,547 | None |
| New patient visit (45+ min) | 24 | $2,950 | $123 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 81 | $2,912 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,910 | $194 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 11 | $2,630 | $239 |
| Infusion, normal saline solution, 250 cc | 110 | $324 | None |
2017: 22 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 94 | $138,107 | $1,469 |
| Return visit (30+ min) | 576 | $107,860 | $89 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 233 | $53,203 | $226 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 94 | $43,456 | $231 |
| Long return visit (40+ min) | 131 | $19,084 | $114 |
| Short return visit (20+ min) | 177 | $15,893 | $60 |
| New patient visit (45+ min) | 81 | $9,914 | $122 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 19 | $9,349 | $492 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 101 | $8,864 | $83 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 121 | $8,854 | $73 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 128 | $7,149 | $55 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 22 | $5,872 | $267 |
| New patient visit (60+ min) | 31 | $5,550 | $179 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 251 | $4,094 | $15 |
| Programming of dual lead pacemaker system | 45 | $4,028 | $50 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,807 | $181 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 19 | $3,626 | $95 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 96 | $2,917 | None |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $1,953 | $108 |
| Short return visit | 11 | $444 | $40 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 17 | $416 | $24 |
| Infusion, normal saline solution, 250 cc | 113 | $325 | None |
2016: 24 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 118 | $168,921 | $1,432 |
| Return visit (30+ min) | 509 | $93,113 | $90 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 118 | $54,548 | $231 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 233 | $52,301 | $224 |
| Short return visit (20+ min) | 416 | $43,097 | $58 |
| New patient visit (45+ min) | 133 | $16,585 | $125 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 24 | $11,741 | $489 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 151 | $11,131 | $73 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 113 | $9,244 | $79 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 22 | $5,239 | $238 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 130 | $5,127 | None |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 24 | $4,580 | $95 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 31 | $3,858 | $113 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 224 | $3,743 | $15 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 75 | $3,601 | $48 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $3,451 | $19 |
| Programming of dual lead pacemaker system | 45 | $3,394 | $48 |
| Complete ultrasound study of arm and leg arteries | 13 | $1,809 | $139 |
| Initial hospital care with same-day admission and discharge with moderate level of medical decision making, per day at least 70 minutes | 11 | $1,655 | $150 |
| Blood test, clotting time | 16 | $1,097 | $5 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 31 | $1,045 | $27 |
| Short return visit | 16 | $915 | $40 |
| Programming of single lead pacemaker system | 13 | $759 | $47 |
| Infusion, normal saline solution, 250 cc | 141 | $411 | None |
2015: 25 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 89 | $127,285 | $1,430 |
| Short return visit (20+ min) | 307 | $48,387 | $65 |
| Return visit (30+ min) | 245 | $45,086 | $92 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 89 | $40,819 | $229 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 143 | $32,971 | $221 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 33 | $16,312 | $494 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 127 | $9,191 | $72 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 33 | $8,502 | $129 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 67 | $5,660 | $76 |
| New patient visit (45+ min) | 41 | $5,620 | $137 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 103 | $5,088 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 17 | $3,716 | $19 |
| Complete ultrasound study of arm and leg arteries | 24 | $3,425 | $143 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,133 | $108 |
| Programming of dual lead pacemaker system | 38 | $3,131 | $47 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,709 | $181 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 143 | $2,560 | $16 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 43 | $2,459 | $56 |
| New patient visit (60+ min) | 11 | $2,086 | $190 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,002 | $65 |
| New patient visit (45+ min) | 17 | $1,822 | $107 |
| Blood test, clotting time | 18 | $1,158 | $5 |
| Short return visit | 11 | $588 | $42 |
| Infusion, normal saline solution, 250 cc | 121 | $271 | None |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 15 | $167 | $6 |
2014: 22 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 112 | $163,333 | $1,458 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 112 | $51,259 | $229 |
| Return visit (30+ min) | 277 | $48,936 | $87 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 193 | $44,540 | $225 |
| Short return visit (20+ min) | 281 | $39,219 | $63 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 39 | $18,839 | $483 |
| Injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) | 127 | $17,691 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 168 | $11,811 | $70 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 39 | $10,062 | $129 |
| New patient visit (45+ min) | 70 | $9,675 | $138 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 84 | $7,289 | $79 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 47 | $5,970 | $119 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 62 | $3,487 | $56 |
| Programming of dual lead pacemaker system | 41 | $3,088 | $52 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $3,010 | $64 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 17 | $2,926 | $19 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 145 | $2,497 | $15 |
| Initial hospital care with same-day admission and discharge with moderate level of medical decision making, per day at least 70 minutes | 11 | $1,799 | $150 |
| Blood test, clotting time | 17 | $773 | $5 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 13 | $352 | $27 |
| Infusion, normal saline solution, 250 cc | 127 | $183 | None |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 16 | $143 | $6 |
2013: 20 services
| Return visit (30+ min) | 317 | $70,836 | $89 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 105 | $55,003 | $509 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 177 | $35,787 | $182 |
| Short return visit (20+ min) | 224 | $33,555 | $65 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 105 | $28,588 | $132 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 48 | $10,973 | $224 |
| Injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270) | 55 | $9,708 | None |
| New patient visit (45+ min) | 70 | $9,673 | $138 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 103 | $9,607 | $84 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 129 | $9,118 | $68 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 46 | $5,858 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $4,066 | $63 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 70 | $3,717 | $51 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 14 | $3,675 | $263 |
| Initial hospital care with same-day admission and discharge with moderate level of medical decision making, per day at least 70 minutes | 25 | $3,636 | $145 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 171 | $3,548 | $17 |
| Complete ultrasound study of arm and leg arteries | 14 | $2,140 | $143 |
| Short return visit | 21 | $1,332 | $42 |
| Programming of dual lead pacemaker system | 14 | $991 | $41 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 19 | $327 | $6 |
Medicaid work
$9,785 in 2024
Medicaid paid $9,785 for 1,212 billed services this clinician did in 2024, up to 187 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 193 | $5,026 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 1,019 | $4,759 |
| 2024 | 1,212 | 2 | 187 | $9,785 |
| 2023 | 1,488 | 2 | 215 | $10,552 |
| 2022 | 766 | 2 | 129 | $8,202 |
| 2021 | 314 | 2 | 90 | $4,321 |
| 2020 | 421 | 1 | 98 | $4,802 |
| 2019 | 24 | 1 | 21 | $333 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 1,260 | $5,300 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 228 | $5,252 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 651 | $4,284 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 115 | $3,919 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 285 | $3,251 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 29 | $1,070 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 421 | $4,802 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 24 | $333 |
Drugs they prescribed that Part D paid
$444,040
Pharmacies billed $444,040 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,691) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
3,288 generic and 403 brand-name prescriptions · $444,040 in drug cost · 41 antibiotic prescriptions to 22 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 255 | $273,347 | $1,072 |
| Xarelto | 56 | $62,340 | $1,113 |
| Repatha Sureclick | 16 | $22,724 | $1,420 |
| Entresto | 36 | $21,739 | $604 |
| Ezetimibe | 388 | $10,799 | $28 |
See all 37 drugs
| Eliquis | 255 | $273,347 | $1,072 |
| Xarelto | 56 | $62,340 | $1,113 |
| Repatha Sureclick | 16 | $22,724 | $1,420 |
| Entresto | 36 | $21,739 | $604 |
| Ezetimibe | 388 | $10,799 | $28 |
| Rosuvastatin | 360 | $6,316 | $18 |
| Metoprolol | 305 | $5,725 | $19 |
| Atorvastatin | 453 | $4,659 | $10 |
| Amlodipine Besylate | 380 | $2,293 | $6 |
| Enalapril Maleate | 73 | $1,684 | $23 |
| Amiodarone | 20 | $1,627 | $81 |
| Losartan | 155 | $1,470 | $9 |
| Metoprolol | 139 | $1,066 | $8 |
| Clopidogrel | 52 | $936 | $18 |
| Nifedipine Er | 18 | $765 | $42 |
| Hydrochlorothiazide | 121 | $698 | $6 |
| Lisinopril | 85 | $695 | $8 |
| Pravastatin | 55 | $593 | $11 |
| Carvedilol | 83 | $586 | $7 |
| Fenofibrate | 19 | $564 | $30 |
| Simvastatin | 52 | $516 | $10 |
| Furosemide | 56 | $503 | $9 |
| Diltiazem 24hr Er (Cd) | 16 | $469 | $29 |
| Propranolol | 34 | $445 | $13 |
| Diltiazem | 13 | $441 | $34 |
| Potassium Chloride | 31 | $409 | $13 |
| Isosorbide Mononitrate Er | 18 | $354 | $20 |
| Triamterene-Hydrochlorothiazid | 27 | $327 | $12 |
| Pantoprazole | 19 | $263 | $14 |
| Warfarin | 20 | $262 | $13 |
| Fenofibrate | 12 | $239 | $20 |
| Atenolol | 20 | $232 | $12 |
| Clonidine | 19 | $215 | $11 |
| Hydralazine | 13 | $182 | $14 |
| Spironolactone | 18 | $130 | $7 |
| Nitroglycerin | 11 | $82 | $7 |
| Amoxicillin | 31 | $48 | $2 |
Year by year
| 2024 | 3,691 | 493 | 0% (0) | 11% | $444,040 |
| 2023 | 4,039 | 536 | 0% (0) | None | $545,991 |
| 2022 | 4,014 | 554 | 0% (0) | None | $639,145 |
| 2021 | 4,046 | 529 | 0% (0) | 14% | $606,166 |
| 2020 | 4,126 | 507 | 0% (0) | 15% | $555,485 |
| 2019 | 4,515 | 526 | 0% (0) | 16% | $516,244 |
| 2018 | 5,351 | 534 | 0% (0) | 16% | $434,452 |
| 2017 | 5,721 | 551 | 0% (0) | 19% | $347,670 |
| 2016 | 5,143 | 479 | 0% (0) | 20% | $251,554 |
| 2015 | 4,026 | 341 | 0% (0) | 19% | $159,920 |
| 2014 | 3,502 | 292 | None | 21% | $140,184 |
| 2013 | 2,686 | 257 | 0% (0) | 23% | $119,068 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 39 drugs
| Eliquis | 252 | $266,890 | $1,059 |
| Xarelto | 84 | $93,156 | $1,109 |
| Entresto | 39 | $30,647 | $786 |
| Repatha Sureclick | 20 | $30,531 | $1,527 |
| Ezetimibe | 360 | $15,112 | $42 |
| Icosapent Ethyl | 15 | $10,530 | $702 |
| Rosuvastatin | 382 | $8,756 | $23 |
| Metoprolol | 345 | $7,144 | $21 |
| Atorvastatin | 505 | $6,688 | $13 |
| Amiodarone | 33 | $3,309 | $100 |
| Amlodipine Besylate | 377 | $3,246 | $9 |
| Losartan | 160 | $2,589 | $16 |
| Enalapril Maleate | 59 | $1,614 | $27 |
| Fenofibrate | 27 | $1,449 | $54 |
| Pravastatin | 71 | $1,262 | $18 |
| Metoprolol | 161 | $1,214 | $8 |
| Nifedipine Er | 17 | $1,206 | $71 |
| Carvedilol | 97 | $1,109 | $11 |
| Nitroglycerin Patch | 15 | $1,079 | $72 |
| Clopidogrel | 54 | $1,018 | $19 |
| Lisinopril | 87 | $936 | $11 |
| Isosorbide Mononitrate Er | 29 | $914 | $32 |
| Diltiazem | 19 | $889 | $47 |
| Diltiazem 24hr Er (Cd) | 22 | $878 | $40 |
| Potassium Chloride | 44 | $748 | $17 |
| Simvastatin | 57 | $711 | $12 |
| Hydrochlorothiazide | 153 | $676 | $4 |
| Furosemide | 78 | $650 | $8 |
| Propranolol | 23 | $561 | $24 |
| Atenolol | 35 | $530 | $15 |
| Cartia Xt | 13 | $454 | $35 |
| Nitroglycerin | 13 | $430 | $33 |
| Clonidine | 17 | $417 | $25 |
| Triamterene-Hydrochlorothiazid | 30 | $391 | $13 |
| Pantoprazole | 22 | $382 | $17 |
| Warfarin | 30 | $378 | $13 |
| Spironolactone | 14 | $113 | $8 |
| Gemfibrozil | 11 | $113 | $10 |
| Amoxicillin | 22 | $26 | $1 |
2022: 39 drugs
| Eliquis | 300 | $320,022 | $1,067 |
| Xarelto | 93 | $107,160 | $1,152 |
| Repatha Sureclick | 29 | $35,668 | $1,230 |
| Entresto | 33 | $23,934 | $725 |
| Ezetimibe | 279 | $16,751 | $60 |
| Praluent | 13 | $11,340 | $872 |
| Rosuvastatin | 282 | $10,783 | $38 |
| Vascepa | 15 | $10,214 | $681 |
| Icosapent Ethyl | 11 | $8,667 | $788 |
| Atorvastatin | 543 | $7,220 | $13 |
| Metoprolol | 340 | $6,455 | $19 |
| Amlodipine Besylate | 397 | $2,749 | $7 |
| Ranolazine Er | 12 | $2,629 | $219 |
| Losartan | 177 | $2,612 | $15 |
| Fenofibrate | 28 | $2,301 | $82 |
| Enalapril Maleate | 60 | $2,204 | $37 |
| Amiodarone | 19 | $1,641 | $86 |
| Nifedipine Er | 19 | $1,548 | $81 |
| Metoprolol | 193 | $1,463 | $8 |
| Pravastatin | 71 | $1,250 | $18 |
| Carvedilol | 102 | $1,155 | $11 |
| Simvastatin | 60 | $1,070 | $18 |
| Clopidogrel | 62 | $994 | $16 |
| Isosorbide Mononitrate Er | 32 | $936 | $29 |
| Hydrochlorothiazide | 177 | $831 | $5 |
| Valsartan | 18 | $805 | $45 |
| Furosemide | 62 | $797 | $13 |
| Fenofibrate | 14 | $756 | $54 |
| Potassium Chloride | 31 | $732 | $24 |
| Lisinopril | 73 | $724 | $10 |
| Propranolol | 19 | $605 | $32 |
| Triamterene-Hydrochlorothiazid | 28 | $539 | $19 |
| Clonidine | 18 | $435 | $24 |
| Diltiazem | 21 | $416 | $20 |
| Nitroglycerin | 22 | $353 | $16 |
| Diltiazem 24hr Er (Cd) | 22 | $316 | $14 |
| Atenolol | 22 | $309 | $14 |
| Warfarin | 41 | $304 | $7 |
| Pantoprazole | 24 | $273 | $11 |
2021: 45 drugs
| Eliquis | 310 | $310,914 | $1,003 |
| Xarelto | 86 | $96,863 | $1,126 |
| Repatha Sureclick | 32 | $27,730 | $867 |
| Pradaxa | 13 | $19,140 | $1,472 |
| Vascepa | 26 | $15,177 | $584 |
| Ezetimibe | 220 | $13,682 | $62 |
| Entresto | 13 | $12,543 | $965 |
| Praluent | 18 | $12,300 | $683 |
| Rosuvastatin | 260 | $8,548 | $33 |
| Metoprolol | 327 | $8,132 | $25 |
| Atorvastatin | 499 | $6,302 | $13 |
| Losartan | 194 | $3,285 | $17 |
| Ranolazine Er | 16 | $3,040 | $190 |
| Amlodipine Besylate | 410 | $3,017 | $7 |
| Fenofibrate | 34 | $2,713 | $80 |
| Pravastatin | 86 | $1,826 | $21 |
| Enalapril Maleate | 60 | $1,817 | $30 |
| Nifedipine Er | 24 | $1,764 | $73 |
| Metoprolol | 197 | $1,527 | $8 |
| Simvastatin | 87 | $1,187 | $14 |
| Clopidogrel | 69 | $1,149 | $17 |
| Diltiazem 24hr Er (Cd) | 15 | $1,028 | $69 |
| Carvedilol | 102 | $1,012 | $10 |
| Fenofibrate | 16 | $992 | $62 |
| Hydrochlorothiazide | 174 | $921 | $5 |
| Amlodipine-Valsartan | 13 | $861 | $66 |
| Dilt-Xr | 11 | $817 | $74 |
| Isosorbide Mononitrate Er | 29 | $806 | $28 |
| Propafenone | 12 | $791 | $66 |
| Furosemide | 86 | $723 | $8 |
| Lisinopril | 79 | $693 | $9 |
| Potassium Chloride | 31 | $595 | $19 |
| Diltiazem | 25 | $544 | $22 |
| Triamterene-Hydrochlorothiazid | 34 | $475 | $14 |
| Atenolol | 34 | $471 | $14 |
| Propranolol | 18 | $448 | $25 |
| Amiodarone | 13 | $434 | $33 |
| Pantoprazole | 29 | $405 | $14 |
| Warfarin | 40 | $397 | $10 |
| Nitroglycerin | 13 | $396 | $30 |
| Fosinopril | 11 | $388 | $35 |
| Clonidine | 18 | $345 | $19 |
| Benazepril | 14 | $273 | $20 |
| Amlodipine Besylate-Benazepril | 11 | $240 | $22 |
| Amoxicillin | 19 | $31 | $2 |
2020: 49 drugs
| Eliquis | 279 | $263,141 | $943 |
| Xarelto | 81 | $80,004 | $988 |
| Vascepa | 41 | $23,007 | $561 |
| Pradaxa | 17 | $22,532 | $1,325 |
| Repatha Sureclick | 21 | $20,735 | $987 |
| Entresto | 22 | $14,752 | $671 |
| Praluent | 16 | $13,827 | $864 |
| Ezetimibe | 218 | $13,784 | $63 |
| Atorvastatin | 541 | $9,180 | $17 |
| Rosuvastatin | 223 | $8,943 | $40 |
| Metoprolol | 307 | $8,162 | $27 |
| Nitroglycerin | 26 | $4,009 | $154 |
| Losartan | 188 | $3,217 | $17 |
| Amlodipine Besylate | 394 | $3,194 | $8 |
| Flecainide Acetate | 27 | $2,975 | $110 |
| Fenofibrate | 36 | $2,698 | $75 |
| Nifedipine Er | 36 | $2,505 | $70 |
| Enalapril Maleate | 63 | $2,393 | $38 |
| Pravastatin | 90 | $2,361 | $26 |
| Omega-3 Acid Ethyl Esters | 13 | $2,256 | $174 |
| Metoprolol | 229 | $1,681 | $7 |
| Simvastatin | 99 | $1,602 | $16 |
| Fenofibrate | 14 | $1,379 | $98 |
| Clopidogrel | 71 | $1,339 | $19 |
| Pindolol | 20 | $1,172 | $59 |
| Lisinopril | 95 | $1,108 | $12 |
| Carvedilol | 93 | $1,095 | $12 |
| Diltiazem | 37 | $1,062 | $29 |
| Hydrochlorothiazide | 145 | $1,039 | $7 |
| Diltiazem 24hr Er (Cd) | 18 | $1,038 | $58 |
| Nitroglycerin Patch | 20 | $1,000 | $50 |
| Dilt-Xr | 12 | $973 | $81 |
| Potassium Chloride | 45 | $936 | $21 |
| Warfarin | 50 | $917 | $18 |
| Furosemide | 86 | $837 | $10 |
| Propranolol | 27 | $815 | $30 |
| Isosorbide Mononitrate Er | 29 | $721 | $25 |
| Amiodarone | 27 | $604 | $22 |
| Atenolol | 46 | $590 | $13 |
| Triamterene-Hydrochlorothiazid | 26 | $423 | $16 |
| Pantoprazole | 24 | $419 | $17 |
| Hydralazine | 12 | $331 | $28 |
| Clonidine | 15 | $327 | $22 |
| Amlodipine Besylate-Benazepril | 17 | $295 | $17 |
| Omeprazole | 12 | $253 | $21 |
| Benazepril | 16 | $230 | $14 |
| Quinapril | 13 | $160 | $12 |
| Lovastatin | 14 | $112 | $8 |
| Amoxicillin | 11 | $32 | $3 |
2019: 47 drugs
| Eliquis | 281 | $204,014 | $726 |
| Xarelto | 113 | $93,279 | $825 |
| Praluent | 31 | $33,699 | $1,087 |
| Vascepa | 67 | $24,363 | $364 |
| Pradaxa | 28 | $19,195 | $686 |
| Repatha Sureclick | 13 | $13,582 | $1,045 |
| Ezetimibe | 184 | $12,272 | $67 |
| Metoprolol | 341 | $10,687 | $31 |
| Atorvastatin | 579 | $10,349 | $18 |
| Rosuvastatin | 220 | $10,129 | $46 |
| Entresto | 15 | $10,002 | $667 |
| Amlodipine Besylate | 477 | $4,415 | $9 |
| Losartan | 191 | $3,169 | $17 |
| Diltiazem 24hr Er (Cd) | 33 | $3,097 | $94 |
| Enalapril Maleate | 67 | $2,605 | $39 |
| Fenofibrate | 46 | $2,452 | $53 |
| Nifedipine Er | 38 | $2,181 | $57 |
| Nitroglycerin | 23 | $2,028 | $88 |
| Simvastatin | 135 | $1,860 | $14 |
| Metoprolol | 267 | $1,783 | $7 |
| Pravastatin | 76 | $1,766 | $23 |
| Pindolol | 18 | $1,571 | $87 |
| Clopidogrel | 75 | $1,523 | $20 |
| Nitroglycerin Patch | 44 | $1,431 | $33 |
| Dilt-Xr | 26 | $1,415 | $54 |
| Lisinopril | 131 | $1,367 | $10 |
| Potassium Chloride | 49 | $1,204 | $25 |
| Isosorbide Mononitrate Er | 35 | $1,187 | $34 |
| Fenofibrate | 17 | $1,147 | $67 |
| Hydrochlorothiazide | 149 | $1,105 | $7 |
| Diltiazem | 32 | $1,074 | $34 |
| Omega-3 Acid Ethyl Esters | 11 | $1,072 | $97 |
| Carvedilol | 102 | $1,007 | $10 |
| Warfarin | 71 | $917 | $13 |
| Atenolol | 58 | $643 | $11 |
| Furosemide | 73 | $619 | $8 |
| Propranolol | 17 | $511 | $30 |
| Triamterene-Hydrochlorothiazid | 28 | $407 | $15 |
| Cartia Xt | 11 | $372 | $34 |
| Clonidine | 16 | $351 | $22 |
| Amiodarone | 19 | $309 | $16 |
| Benazepril | 17 | $298 | $18 |
| Amlodipine Besylate-Benazepril | 13 | $291 | $22 |
| Sotalol | 14 | $245 | $18 |
| Lovastatin | 12 | $182 | $15 |
| Gemfibrozil | 11 | $107 | $10 |
| Amoxicillin | 26 | $48 | $2 |
2018: 56 drugs
| Eliquis | 324 | $167,954 | $518 |
| Xarelto | 121 | $70,429 | $582 |
| Pradaxa | 29 | $19,829 | $684 |
| Ezetimibe | 145 | $15,964 | $110 |
| Metoprolol | 375 | $11,214 | $30 |
| Atorvastatin | 652 | $10,298 | $16 |
| Rosuvastatin | 224 | $7,518 | $34 |
| Entresto | 14 | $4,688 | $335 |
| Amlodipine Besylate | 568 | $4,495 | $8 |
| Livalo | 13 | $3,841 | $295 |
| Bystolic | 11 | $3,251 | $296 |
| Fenofibrate | 56 | $3,148 | $56 |
| Diltiazem 24hr Er (Cd) | 49 | $3,060 | $62 |
| Nifedipine Er | 49 | $2,950 | $60 |
| Enalapril Maleate | 80 | $2,886 | $36 |
| Losartan | 263 | $2,807 | $11 |
| Niacin Er | 17 | $2,406 | $142 |
| Clopidogrel | 107 | $2,405 | $22 |
| Diltiazem | 56 | $2,140 | $38 |
| Pravastatin | 80 | $1,838 | $23 |
| Warfarin | 139 | $1,828 | $13 |
| Metoprolol | 351 | $1,801 | $5 |
| Pindolol | 15 | $1,551 | $103 |
| Potassium Chloride | 53 | $1,512 | $29 |
| Simvastatin | 152 | $1,459 | $10 |
| Isosorbide Mononitrate Er | 51 | $1,382 | $27 |
| Lisinopril | 164 | $1,351 | $8 |
| Nitroglycerin Patch | 30 | $1,213 | $40 |
| Hydrochlorothiazide | 182 | $1,140 | $6 |
| Carvedilol | 122 | $1,097 | $9 |
| Omega-3 Acid Ethyl Esters | 12 | $968 | $81 |
| Nitroglycerin | 26 | $919 | $35 |
| Toprol Xl | 15 | $854 | $57 |
| Furosemide | 121 | $789 | $7 |
| Flecainide Acetate | 12 | $691 | $58 |
| Atenolol | 62 | $623 | $10 |
| Cartia Xt | 24 | $589 | $25 |
| Dilt-Xr | 16 | $546 | $34 |
| Triamterene-Hydrochlorothiazid | 35 | $532 | $15 |
| Valsartan | 18 | $441 | $25 |
| Digoxin | 12 | $431 | $36 |
| Benazepril | 29 | $412 | $14 |
| Amlodipine Besylate-Benazepril | 18 | $395 | $22 |
| Candesartan Cilexetil | 12 | $387 | $32 |
| Amiodarone | 30 | $386 | $13 |
| Hydralazine | 16 | $384 | $24 |
| Esomeprazole Magnesium | 12 | $383 | $32 |
| Propranolol | 26 | $382 | $15 |
| Losartan-Hydrochlorothiazide | 17 | $321 | $19 |
| Ramipril | 15 | $296 | $20 |
| Clonidine | 18 | $215 | $12 |
| Omeprazole | 17 | $209 | $12 |
| Lovastatin | 11 | $156 | $14 |
| Gemfibrozil | 12 | $119 | $10 |
| Pantoprazole | 12 | $107 | $9 |
| Amoxicillin | 18 | $23 | $1 |
2017: 55 drugs
| Eliquis | 279 | $123,843 | $444 |
| Zetia | 77 | $39,033 | $507 |
| Xarelto | 62 | $28,960 | $467 |
| Pradaxa | 31 | $17,141 | $553 |
| Metoprolol | 422 | $11,457 | $27 |
| Atorvastatin | 660 | $9,770 | $15 |
| Rosuvastatin | 184 | $8,842 | $48 |
| Ezetimibe | 48 | $8,794 | $183 |
| Bystolic | 13 | $4,350 | $335 |
| Fenofibrate | 77 | $3,964 | $51 |
| Amlodipine Besylate | 627 | $3,880 | $6 |
| Enalapril Maleate | 121 | $3,741 | $31 |
| Niacin Er | 19 | $3,423 | $180 |
| Potassium Chloride | 85 | $2,479 | $29 |
| Warfarin | 202 | $2,477 | $12 |
| Clopidogrel | 149 | $2,234 | $15 |
| Pindolol | 16 | $2,190 | $137 |
| Losartan | 217 | $2,070 | $10 |
| Metoprolol | 427 | $1,948 | $5 |
| Diltiazem 24hr Er | 39 | $1,682 | $43 |
| Pravastatin | 89 | $1,617 | $18 |
| Lisinopril | 212 | $1,499 | $7 |
| Valsartan | 48 | $1,430 | $30 |
| Isosorbide Mononitrate Er | 47 | $1,284 | $27 |
| Simvastatin | 181 | $1,242 | $7 |
| Furosemide | 207 | $1,185 | $6 |
| Carvedilol | 150 | $1,157 | $8 |
| Nifedipine Er | 31 | $1,124 | $36 |
| Omega-3 Acid Ethyl Esters | 12 | $1,008 | $84 |
| Nitroglycerin Patch | 23 | $896 | $39 |
| Hydrochlorothiazide | 158 | $871 | $6 |
| Isosorbide Dinitrate | 17 | $871 | $51 |
| Diltiazem | 52 | $839 | $16 |
| Flecainide Acetate | 16 | $810 | $51 |
| Atenolol | 103 | $758 | $7 |
| Cartia Xt | 32 | $751 | $23 |
| Candesartan Cilexetil | 12 | $712 | $59 |
| Digoxin | 15 | $698 | $47 |
| Triamterene-Hydrochlorothiazid | 45 | $651 | $14 |
| Levothyroxine | 18 | $538 | $30 |
| Diltiazem Er | 26 | $520 | $20 |
| Propranolol Hcl Er | 11 | $479 | $44 |
| Amlodipine Besylate-Benazepril | 22 | $414 | $19 |
| Sotalol | 11 | $405 | $37 |
| Amiodarone | 24 | $373 | $16 |
| Clonidine | 15 | $365 | $24 |
| Propranolol | 15 | $364 | $24 |
| Fosinopril | 21 | $320 | $15 |
| Ramipril | 16 | $293 | $18 |
| Nitroglycerin | 11 | $240 | $22 |
| Benazepril | 24 | $230 | $10 |
| Tricor | 11 | $188 | $17 |
| Spironolactone | 14 | $166 | $12 |
| Toprol Xl | 12 | $157 | $13 |
| Losartan-Hydrochlorothiazide | 11 | $108 | $10 |
2016: 53 drugs
| Eliquis | 161 | $57,696 | $358 |
| Zetia | 85 | $34,270 | $403 |
| Crestor | 118 | $32,636 | $277 |
| Pradaxa | 23 | $12,802 | $557 |
| Xarelto | 22 | $12,308 | $559 |
| Atorvastatin | 660 | $9,882 | $15 |
| Metoprolol | 316 | $7,378 | $23 |
| Rosuvastatin | 52 | $5,680 | $109 |
| Fenofibrate | 87 | $3,805 | $44 |
| Enalapril Maleate | 146 | $3,700 | $25 |
| Bystolic | 18 | $3,579 | $199 |
| Amlodipine Besylate | 388 | $2,823 | $7 |
| Warfarin | 280 | $2,664 | $10 |
| Clopidogrel | 155 | $2,612 | $17 |
| Niacin Er | 25 | $2,571 | $103 |
| Pravastatin | 109 | $2,215 | $20 |
| Losartan | 210 | $1,831 | $9 |
| Metoprolol | 368 | $1,593 | $4 |
| Pindolol | 15 | $1,486 | $99 |
| Digoxin | 35 | $1,485 | $42 |
| Potassium Chloride | 70 | $1,424 | $20 |
| Simvastatin | 166 | $1,128 | $7 |
| Valsartan | 41 | $1,065 | $26 |
| Isosorbide Mononitrate Er | 37 | $1,024 | $28 |
| Nitroglycerin Patch | 19 | $1,023 | $54 |
| Carvedilol | 152 | $1,018 | $7 |
| Furosemide | 236 | $1,015 | $4 |
| Lisinopril | 137 | $975 | $7 |
| Cartia Xt | 33 | $913 | $28 |
| Diltiazem 24hr Er | 29 | $875 | $30 |
| Atenolol | 101 | $796 | $8 |
| Hydrochlorothiazide | 147 | $763 | $5 |
| Diltiazem | 66 | $687 | $10 |
| Nifedipine Er | 13 | $621 | $48 |
| Propranolol Hcl Er | 12 | $560 | $47 |
| Levothyroxine | 23 | $514 | $22 |
| Captopril | 14 | $455 | $33 |
| Triamterene-Hydrochlorothiazid | 39 | $424 | $11 |
| Nifedical Xl | 16 | $370 | $23 |
| Diltiazem Er | 16 | $364 | $23 |
| Taztia Xt | 12 | $340 | $28 |
| Ramipril | 19 | $318 | $17 |
| Propranolol | 12 | $305 | $25 |
| Irbesartan | 14 | $240 | $17 |
| Amlodipine Besylate-Benazepril | 17 | $232 | $14 |
| Benazepril | 35 | $225 | $6 |
| Lovastatin | 23 | $222 | $10 |
| Amiodarone | 20 | $220 | $11 |
| Fosinopril | 16 | $159 | $10 |
| Losartan-Hydrochlorothiazide | 19 | $158 | $8 |
| Omeprazole | 20 | $121 | $6 |
| Lisinopril-Hydrochlorothiazide | 12 | $65 | $5 |
| Amoxicillin | 15 | $18 | $1 |
2015: 54 drugs
| Eliquis | 108 | $34,861 | $323 |
| Zetia | 47 | $16,452 | $350 |
| Crestor | 66 | $14,974 | $227 |
| Pradaxa | 23 | $13,382 | $582 |
| Atorvastatin | 550 | $8,672 | $16 |
| Xarelto | 14 | $7,881 | $563 |
| Fenofibrate | 70 | $5,684 | $81 |
| Niacin Er | 37 | $5,286 | $143 |
| Metoprolol | 197 | $4,414 | $22 |
| Warfarin | 304 | $3,036 | $10 |
| Bystolic | 15 | $2,094 | $140 |
| Pindolol | 31 | $1,972 | $64 |
| Pravastatin | 77 | $1,666 | $22 |
| Amlodipine Besylate | 249 | $1,547 | $6 |
| Losartan | 171 | $1,539 | $9 |
| Metoprolol | 327 | $1,301 | $4 |
| Digoxin | 29 | $1,252 | $43 |
| Potassium Chloride | 36 | $1,209 | $34 |
| Clopidogrel | 87 | $1,198 | $14 |
| Enalapril Maleate | 57 | $1,166 | $20 |
| Hydrochlorothiazide | 157 | $932 | $6 |
| Simvastatin | 113 | $866 | $8 |
| Diltiazem | 81 | $798 | $10 |
| Cartia Xt | 30 | $775 | $26 |
| Carvedilol | 141 | $757 | $5 |
| Diltiazem 24hr Er | 28 | $628 | $22 |
| Furosemide | 169 | $616 | $4 |
| Isosorbide Mononitrate Er | 27 | $611 | $23 |
| Propranolol Hcl Er | 12 | $560 | $47 |
| Lisinopril | 122 | $538 | $4 |
| Valsartan | 22 | $481 | $22 |
| Atenolol | 69 | $425 | $6 |
| Diltiazem Er | 13 | $418 | $32 |
| Nitroglycerin Patch | 13 | $400 | $31 |
| Diltiazem 24hr Cd | 13 | $388 | $30 |
| Levothyroxine | 16 | $363 | $23 |
| Taztia Xt | 12 | $340 | $28 |
| Valsartan-Hydrochlorothiazide | 11 | $320 | $29 |
| Dilt-Xr | 11 | $318 | $29 |
| Omeprazole | 23 | $314 | $14 |
| Propafenone | 29 | $302 | $10 |
| Amlodipine Besylate-Benazepril | 14 | $261 | $19 |
| Benazepril | 57 | $229 | $4 |
| Nifedical Xl | 13 | $225 | $17 |
| Sotalol | 15 | $224 | $15 |
| Metformin | 15 | $156 | $10 |
| Triamterene-Hydrochlorothiazid | 15 | $152 | $10 |
| Allopurinol | 13 | $150 | $12 |
| Amiodarone | 12 | $149 | $12 |
| Fosinopril | 13 | $145 | $11 |
| Gabapentin | 13 | $77 | $6 |
| Terazosin | 11 | $68 | $6 |
| Famotidine | 12 | $48 | $4 |
| Hydralazine | 12 | $41 | $3 |
2014: 49 drugs
| Zetia | 48 | $15,370 | $320 |
| Pradaxa | 33 | $13,468 | $408 |
| Eliquis | 33 | $10,820 | $328 |
| Atorvastatin | 509 | $9,461 | $19 |
| Crestor | 46 | $8,472 | $184 |
| Fenofibrate | 53 | $6,106 | $115 |
| Metoprolol | 202 | $5,505 | $27 |
| Niacin Er | 24 | $4,412 | $184 |
| Diovan | 19 | $3,433 | $181 |
| Warfarin | 273 | $2,738 | $10 |
| Plavix | 13 | $2,372 | $182 |
| Potassium Chloride | 51 | $1,956 | $38 |
| Pindolol | 33 | $1,819 | $55 |
| Losartan | 154 | $1,735 | $11 |
| Matzim La | 12 | $1,625 | $135 |
| Metoprolol | 308 | $1,618 | $5 |
| Amlodipine-Atorvastatin | 11 | $1,526 | $139 |
| Amlodipine Besylate | 174 | $1,506 | $9 |
| Clopidogrel | 75 | $1,363 | $18 |
| Pravastatin | 50 | $1,138 | $23 |
| Carvedilol | 128 | $966 | $8 |
| Digoxin | 20 | $931 | $47 |
| Enalapril Maleate | 69 | $749 | $11 |
| Simvastatin | 81 | $732 | $9 |
| Hydrochlorothiazide | 107 | $715 | $7 |
| Diltiazem 24hr Cd | 22 | $659 | $30 |
| Diltiazem 24hr Er | 32 | $651 | $20 |
| Isosorbide Mononitrate Er | 30 | $635 | $21 |
| Nitroglycerin Patch | 13 | $504 | $39 |
| Levothyroxine | 35 | $498 | $14 |
| Propafenone | 29 | $487 | $17 |
| Benazepril | 59 | $480 | $8 |
| Nifedical Xl | 24 | $462 | $19 |
| Lisinopril | 89 | $451 | $5 |
| Diltiazem | 56 | $407 | $7 |
| Escitalopram | 13 | $375 | $29 |
| Venlafaxine Hcl Er | 12 | $369 | $31 |
| Atenolol | 55 | $359 | $7 |
| Sotalol | 12 | $344 | $29 |
| Furosemide | 86 | $331 | $4 |
| Cartia Xt | 14 | $307 | $22 |
| Klor-Con 10 | 15 | $214 | $14 |
| Metolazone | 12 | $213 | $18 |
| Metformin | 13 | $210 | $16 |
| Triamterene-Hydrochlorothiazid | 16 | $194 | $12 |
| Pantoprazole | 11 | $171 | $16 |
| Omeprazole | 18 | $109 | $6 |
| Hydralazine | 12 | $56 | $5 |
| Famotidine | 11 | $44 | $4 |
2013: 41 drugs
| Pradaxa | 50 | $16,952 | $339 |
| Zetia | 46 | $12,972 | $282 |
| Atorvastatin | 366 | $12,101 | $33 |
| Fenofibrate | 45 | $6,282 | $140 |
| Niaspan | 24 | $6,034 | $251 |
| Diovan | 24 | $5,753 | $240 |
| Crestor | 26 | $5,096 | $196 |
| Metoprolol | 140 | $4,730 | $34 |
| Clopidogrel | 46 | $3,423 | $74 |
| Lovaza | 15 | $3,142 | $209 |
| Warfarin | 256 | $2,636 | $10 |
| Plavix | 12 | $2,378 | $198 |
| Pindolol | 34 | $2,046 | $60 |
| Losartan | 112 | $1,939 | $17 |
| Potassium Chloride | 30 | $1,586 | $53 |
| Amlodipine Besylate | 140 | $1,371 | $10 |
| Metoprolol | 244 | $1,326 | $5 |
| Carvedilol | 96 | $959 | $10 |
| Simvastatin | 85 | $913 | $11 |
| Diltiazem 24hr Er | 31 | $734 | $24 |
| Enalapril Maleate | 75 | $695 | $9 |
| Nitroglycerin Patch | 24 | $646 | $27 |
| Pravastatin | 44 | $623 | $14 |
| Verapamil Er | 16 | $602 | $38 |
| Propafenone | 19 | $541 | $28 |
| Isosorbide Mononitrate Er | 23 | $511 | $22 |
| Diltiazem 24hr Cd | 13 | $497 | $38 |
| Lisinopril | 80 | $484 | $6 |
| Furosemide | 86 | $422 | $5 |
| Diltiazem | 50 | $383 | $8 |
| Nifedical Xl | 17 | $354 | $21 |
| Metolazone | 17 | $349 | $21 |
| Sotalol | 11 | $342 | $31 |
| Hydrochlorothiazide | 41 | $277 | $7 |
| Triamterene-Hctz | 20 | $230 | $11 |
| Atenolol | 33 | $215 | $7 |
| Klor-Con 10 | 15 | $214 | $14 |
| Levothyroxine | 24 | $207 | $9 |
| Benazepril | 27 | $192 | $7 |
| Amiodarone | 12 | $162 | $14 |
| Hydralazine | 12 | $97 | $8 |
Money from drug and device companies
$996 in 2025
| 2025 | 10 | 28 | None | $996 |
| 2024 | 11 | 49 | None | $2,280 |
| 2023 | 9 | 35 | None | $937 |
| 2022 | 8 | 13 | None | $434 |
| 2021 | 2 | 3 | None | $96 |
| 2020 | 9 | 37 | None | $786 |
| 2019 | 11 | 81 | None | $1,166 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novo Nordisk | Wegovy | $235 | 2 payments
|
| Biotronik | Acticor 7 Vr-T Dx | $167 | 1 payment
|
| Merck Sharp & Dohme | Verquvo | $122 | 5 payments
|
| Novartis Pharmaceuticals | Leqvio | $104 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $97 | 5 payments
|
| Boston Scientific | Watchman Flx | $82 | 3 payments
|
See all 28 published payments
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-18 | Eliquis | $18 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-20 | Eliquis | $17 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-18 | Kerendia | $14 |
| Merck Sharp & Dohme | Meals · 2025-11-05 | Capvaxive | $26 |
| Novo Nordisk | Meals · 2025-10-21 | Ozempic | $116 |
| Novartis Pharmaceuticals | Meals · 2025-10-15 | Leqvio | $32 |
| Biotronik | Meals · 2025-09-18 | Acticor 7 Vr-T Dx | $167 |
| Merck Sharp & Dohme | Meals · 2025-09-09 | Verquvo | $28 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-03 | Eliquis | $21 |
| GlaxoSmithKline | Meals · 2025-08-19 | Shingrix | $28 |
| Novartis Pharmaceuticals | Meals · 2025-08-12 | Leqvio | $20 |
| Amgen | Meals · 2025-07-29 | Repatha | $17 |
| Pfizer | Meals · 2025-07-22 | Eliquis | $24 |
| Merck Sharp & Dohme | Meals · 2025-07-17 | Verquvo | $21 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-16 | Eliquis | $23 |
| Boston Scientific | Meals · 2025-07-03 | Watchman Flx | $21 |
| Amgen | Meals · 2025-06-04 | Repatha | $23 |
| Merck Sharp & Dohme | Meals · 2025-05-28 | Verquvo | $22 |
| Pfizer | Meals · 2025-05-22 | Eliquis | $28 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-13 | Camzyos | $19 |
| Novartis Pharmaceuticals | Meals · 2025-05-01 | Leqvio | $23 |
| Boston Scientific | Meals · 2025-04-22 | Watchman Flx | $38 |
| Novo Nordisk | Meals · 2025-04-17 | Wegovy | $119 |
| Merck Sharp & Dohme | Meals · 2025-03-24 | Verquvo | $26 |
| Novartis Pharmaceuticals | Meals · 2025-03-12 | Leqvio | $29 |
| Amgen | Meals · 2025-02-27 | Repatha | $27 |
| Pfizer | Meals · 2025-02-24 | Eliquis | $28 |
| Boston Scientific | Meals · 2025-02-11 | Watchman Flx | $23 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,280
| Boston Scientific | Watchman Access System | $1,229 | 12 payments
|
| Pfizer | Eliquis | $212 | 12 payments
|
| Abbott Laboratories | Amplatzer Amulet | $205 | 2 payments
|
| Amgen | Repatha | $200 | 10 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $153 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $86 | 4 payments
|
| Merck Sharp & Dohme | Verquvo | $70 | 3 payments
|
| Novartis Pharmaceuticals | Leqvio | $62 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $27 | 1 payment
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $21 | 1 payment
|
| Esperion Therapeutics | Nexletol | $15 | 1 payment
|
2023: $937
| Boston Scientific | Watchman Flx | $234 | 5 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $218 | 8 payments
|
| Pfizer | Eliquis | $160 | 12 payments
|
| Novo Nordisk | None | $125 | 1 payment
|
| Novartis Pharmaceuticals | Leqvio | $76 | 3 payments
|
| Merck Sharp & Dohme | Verquvo | $43 | 2 payments
|
| Amgen | Repatha | $40 | 2 payments
|
| Kiniksa Pharmaceuticals | Arcalyst | $26 | 1 payment
|
| Esperion Therapeutics | Nexletol | $14 | 1 payment
|
2022: $434
| Biotronik | Rivacor 7 Dr-T | $159 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $75 | 4 payments
|
| Pfizer | Eliquis | $50 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $43 | 1 payment
|
| Merck Sharp & Dohme | Verquvo | $36 | 2 payments
|
| Amgen | Repatha | $31 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $28 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $12 | 1 payment
|
2021: $96
| Pfizer | Eliquis | $61 | 2 payments
|
| Boston Scientific | Watchman | $35 | 1 payment
|
2020: $786
| Amarin Pharma | Vascepa | $258 | 16 payments
|
| Pfizer | Eliquis | $192 | 6 payments
|
| Janssen Pharmaceuticals | Xarelto | $156 | 8 payments
|
| Biotronik | None | $49 | 1 payment
|
| Amgen | Repatha | $46 | 2 payments
|
| Boston Scientific | Watchman | $25 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $21 | 1 payment
|
| Esperion Therapeutics | Nexletol | $21 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $18 | 1 payment
|
2019: $1,166
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $401 | 40 payments
|
| Janssen Pharmaceuticals | Xarelto | $133 | 8 payments
|
| Abiomed | Impella | $125 | 1 payment
|
| Amarin Pharma | Vascepa | $118 | 13 payments
|
| Pfizer | Chantix | $111 | 9 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $101 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $70 | 4 payments
|
| Kowa Pharmaceuticals America | Livalo | $42 | 2 payments
|
| Biotronik | None | $23 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $22 | 1 payment
|
| Regeneron Healthcare Solutions | Praluent | $20 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1962448530
- Licence
- CA G70729California G70729: Current · expires 2028-10-31
- Trained
- New York Medical College, 1985
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 173 N Morrison Ave, Suite C, San Jose, CA, 95126
- NPI first listed
- 2006-06-21
- NPI last updated
- 2016-08-17
This is when the NPI record was last certified, not a medical board exam.